Princeton, NJ, December 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, is attending the 41st Annual J.P. Morgan Health Care Conference, JPM Week, in January 2023.
iQure’s portfolio of treatments in Epilepsy, Pain and other neurodegenerative diseases has had a number of positive developments in the last few months. As a result, iQure Pharma has intensified its focus in the areas of strategic partnering and fundraising. Pawel Zolnierczyk, CEO and Henk de Wilde, COO and R&D Director, will participate in JPM Week to further explore strategic collaborations with pharma and expand current fundraising activities.
“These are exciting times for iQure with very promising market traction and significant interest from pharma for both of our assets,” said iQure CEO Pawel Zolnierczyk. “We are currently in active discussions with large pharma and look forward to continuing these at JPM. While we are there, we will be meeting with VCs and CVCs to expand our fundraising efforts.”
For those interested in meeting with iQure Pharma in San Francisco during JPM Week, please register here:
About iQure Pharma
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.